Last updated: September 29, 2026
Tagamet, the brand name for cimetidine, is a mature H2-receptor antagonist with limited pharmaceutical exclusivity and low current innovation value. Its commercial peak occurred after FDA approval in 1977, when prescription cimetidine became one of the first blockbuster medicines. Generic entry, newer H2 blockers such as famotidine, and proton-pump inhibitors later eliminated most prescription pricing power. The remaining commercial opportunity is concentrated in over-the-counter Tagamet HB and related consumer-health channels.
Public companies do not generally disclose Tagamet revenue as a standalone line item. The brand’s current financial trajectory is therefore best assessed through market position, channel economics, generic substitution, regulatory status, and ownership history rather than a verified annual revenue series.
What is Tagamet and how does cimetidine work?
Tagamet is the original branded version of cimetidine, an H2-receptor antagonist used to reduce gastric acid secretion. It was developed by SmithKline Beecham predecessor Smith Kline & French and received U.S. Food and Drug Administration approval in 1977 for conditions including gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, and pathological hypersecretory conditions.[1]
Cimetidine blocks histamine H2 receptors on gastric parietal cells. The drug reduces both basal and stimulated acid secretion. Its early commercial success came from its ability to treat peptic-ulcer disease without the surgical or dietary restrictions associated with older therapies.
What dosage forms does Tagamet have?
Tagamet has historically been marketed in:
- Prescription tablets
- Prescription oral solutions
- Injection products
- Over-the-counter Tagamet HB tablets
- Multiple strengths, including 200 mg, 300 mg, 400 mg, and 800 mg prescription tablets and 200 mg OTC tablets
The commercially relevant branded product today is primarily Tagamet HB. Prescription cimetidine is supplied mainly by generic manufacturers.
When did Tagamet reach peak sales?
Tagamet became a major pharmaceutical product during the 1980s. Historical industry accounts identify cimetidine as one of the first medicines to achieve annual sales above $1 billion, reflecting both strong medical demand and the absence of effective generic competition during its main growth period.[2]
| Period |
Market position |
Financial implication |
| 1977-1982 |
New prescription H2 blocker |
Rapid physician adoption and high branded pricing |
| 1980s |
Leading ulcer and acid-control therapy |
Blockbuster revenue and strong margin contribution |
| Early 1990s |
Mature branded product |
Slower growth as competitors expanded |
| Mid-to-late 1990s |
Generic competition and new therapies |
Sharp erosion in branded prescription revenue |
| 2000s |
Consumer-health and residual generic market |
Lower price, wider distribution, reduced exclusivity |
| 2010s-present |
Mature OTC brand with generic prescription alternatives |
Stable but limited growth potential |
The financial profile changed from high-margin prescription innovation to a lower-growth consumer-health brand. The key transition was the loss of exclusivity and the migration of acid-control treatment toward famotidine and proton-pump inhibitors.
What patents protected Tagamet and when did they expire?
Tagamet’s principal composition-of-matter and product exclusivity rights expired decades ago. The original cimetidine patent estate no longer provides a meaningful barrier to generic entry in the United States or other major pharmaceutical markets.
| IP category |
Historical protection |
Current commercial effect |
| Cimetidine active-ingredient patents |
Filed and issued in the 1970s |
Expired |
| Prescription formulation patents |
Historically covered dosage forms and compositions |
Expired or commercially immaterial |
| Method-of-use patents |
Covered acid-related indications |
Expired |
| Manufacturing patents |
May have covered synthesis routes or intermediates |
No material barrier to ordinary generic supply |
| OTC brand trademarks |
Protect the Tagamet name and trade dress |
Remain commercially relevant |
| Current Orange Book protection |
No meaningful active exclusivity expected for cimetidine |
Generic competition remains established |
The cimetidine patent estate is distinct from the Tagamet trademark. Patent rights protect the drug technology; trademark rights protect the brand identity. Tagamet’s remaining value is primarily trademark-based.
What is the Orange Book status of Tagamet?
The FDA Orange Book is relevant to approved prescription drug products and associated patents and exclusivity. Cimetidine products have long been subject to generic competition. Tagamet HB, as an OTC product, does not rely on an active prescription-style Orange Book patent strategy to maintain market exclusivity.[3]
The practical Orange Book conclusion is:
- No active composition patent protects cimetidine.
- No meaningful regulatory exclusivity blocks abbreviated new drug applications for generic cimetidine.
- Generic cimetidine products have been available for many years.
- Current Tagamet value derives from branding, distribution, consumer recognition, and OTC positioning.
How did generic entry change Tagamet’s market?
Generic entry permanently reduced the prescription value of Tagamet. Once cimetidine became available from multiple manufacturers, payers and pharmacies had limited economic reasons to favor the branded product.
Generic erosion affected Tagamet through four mechanisms:
- Pharmacy substitution reduced branded prescription volume.
- Formularies shifted toward low-cost generic cimetidine and competing H2 antagonists.
- Physicians adopted newer products with fewer interaction concerns.
- Direct-to-consumer demand moved toward OTC alternatives and proton-pump inhibitors.
Cimetidine also has a broad drug-interaction profile because it inhibits several cytochrome P450 enzymes. Famotidine, another H2 blocker, generally gained preference where clinicians wanted a similar mechanism with fewer interaction concerns.[4]
How does Tagamet compare with Pepcid, Zantac, and proton-pump inhibitors?
Tagamet competes across different layers of the acid-reduction market.
| Product |
Active ingredient |
Class |
Current competitive position |
| Tagamet |
Cimetidine |
H2-receptor antagonist |
Mature branded OTC product; generic prescription competition |
| Pepcid |
Famotidine |
H2-receptor antagonist |
Stronger current H2 brand position and broader consumer recognition |
| Zantac |
Ranitidine |
H2-receptor antagonist |
Original ranitidine products withdrawn from the U.S. market after NDMA contamination concerns |
| Prilosec OTC |
Omeprazole |
Proton-pump inhibitor |
Strong OTC position for frequent heartburn |
| Nexium 24HR |
Esomeprazole |
Proton-pump inhibitor |
Premium OTC acid-control brand |
| Prevacid 24HR |
Lansoprazole |
Proton-pump inhibitor |
Established OTC proton-pump inhibitor competitor |
Pepcid is the closest branded competitor. Proton-pump inhibitors compete on stronger and longer acid suppression, especially for frequent heartburn and gastroesophageal reflux disease. Tagamet retains relevance for consumers seeking an H2 blocker, but it has less differentiation than Pepcid and less clinical intensity than proton-pump inhibitors.
Did the Zantac withdrawal benefit Tagamet?
The withdrawal of ranitidine products from the U.S. market created an opportunity for alternative H2 blockers, including famotidine and cimetidine. The benefit to Tagamet was constrained by Pepcid’s stronger brand position and by the broader consumer shift toward proton-pump inhibitors.
The Zantac withdrawal changed category demand, but it did not restore Tagamet’s former prescription economics. The event expanded consumer awareness of alternative H2 products rather than recreating cimetidine’s historical market structure.[5]
Who owns and markets the Tagamet brand?
Tagamet’s commercial ownership has moved through the pharmaceutical and consumer-health sectors. The brand was historically associated with SmithKline Beecham and later GlaxoSmithKline. GSK transferred various consumer-health brands to Prestige Brands in a transaction announced in 2011 and completed in 2012.[6]
The ownership transition reflects Tagamet’s changed economic identity:
- Historical role: innovative prescription medicine
- Later role: mature branded pharmaceutical
- Current role: consumer-health asset supported by trademark recognition and retail distribution
Prestige Brands has historically reported consumer products by portfolio and category rather than providing a complete, recurring standalone Tagamet revenue series. That reporting structure limits public visibility into Tagamet’s precise annual sales, gross margin, and contribution to enterprise value.[7]
What is Tagamet’s current financial trajectory?
Tagamet’s financial trajectory is best described as a decline from blockbuster prescription economics to a smaller, mature OTC revenue stream.
Revenue drivers
Current revenue is influenced by:
- OTC distribution through pharmacies, mass retailers, and e-commerce
- Brand recognition among older consumers
- Consumer preference for H2 blockers
- Heartburn and acid-indigestion incidence
- Promotional spending and shelf placement
- Retailer private-label competition
- Price differences versus famotidine
- Stock availability and product-line breadth
Margin drivers
Margins are likely lower than during the prescription era because OTC sales require retail trade spending, promotional support, packaging, and consumer marketing. Generic cimetidine creates a low-price reference point, limiting the ability to charge a large premium solely for the active ingredient.
Financial outlook
| Scenario |
Market development |
Expected financial effect |
| Base case |
Stable mature OTC demand with strong generic pressure |
Low growth or gradual decline |
| Upside case |
H2-category expansion and improved retail execution |
Moderate volume recovery |
| Downside case |
Continued consumer migration to famotidine and proton-pump inhibitors |
Faster brand erosion |
| Severe downside |
Distribution losses, manufacturing disruption, or regulatory issue |
Material sales contraction |
Tagamet has no obvious path back to historical blockbuster revenue without a new formulation, a clinically differentiated use, or a major category event. Its value is more consistent with a defensible mature consumer brand than with an innovation-driven pharmaceutical asset.
Are there current FDA regulatory risks for Tagamet?
Tagamet’s central regulatory risk is not patent expiry. It is compliance with OTC labeling, manufacturing controls, supply continuity, and product quality requirements.
Relevant regulatory considerations include:
- Compliance with applicable OTC acid-reducer requirements
- Accurate labeling for age, dosage, duration, and contraindications
- Drug-interaction warnings associated with cimetidine
- Good manufacturing practice compliance
- Stability and supply-chain controls
- Adverse-event monitoring
- Retail and digital-commerce claims enforcement
Cimetidine’s interaction profile requires particular attention in labeling and medical communications. FDA-approved prescription and OTC uses do not eliminate the need to manage interaction warnings, especially for consumers taking drugs metabolized through affected cytochrome P450 pathways.[1][4]
What generic entry risks exist for Tagamet?
The risk from generic entry is structural rather than event-driven. Generic cimetidine is already established, so a future Paragraph IV challenge is unlikely to produce a new market shock comparable to the original patent expiry.
Paragraph IV litigation outlook
Paragraph IV certifications apply when a generic applicant challenges listed patents for an approved drug. For a mature cimetidine product with expired core patents and no material active Orange Book protection, the principal Paragraph IV opportunity has largely passed.
Potential future disputes would more likely involve:
- A specific formulation
- A combination product
- A device or delivery system
- A newly approved indication
- A manufacturing process
- Trade dress or trademark rights, rather than drug patents
Trademark litigation could affect brand presentation, but it would not restore market exclusivity for cimetidine.
What manufacturing and intellectual-property barriers remain?
The active ingredient is technically established, and cimetidine manufacturing does not present the type of complex biologic or sterile-product barrier associated with injectable biologics. Manufacturing competition is therefore higher than in products requiring specialized cell culture, device integration, or complex delivery systems.
Remaining barriers include:
- Supplier qualification
- Regulatory compliance
- Quality consistency
- Retail distribution
- Working-capital requirements
- Consumer marketing
- Trademark recognition
- Shelf placement
- Reliable supply of finished dosage forms
These barriers support brand persistence but do not prevent generic substitution.
Are biosimilars relevant to Tagamet?
No. Tagamet contains cimetidine, a small-molecule chemical active ingredient. It is not a biologic and has no biosimilar pathway. Competition occurs through generic drug approval and OTC substitution, not through the FDA biosimilar framework.
This distinction matters for investment and licensing analysis. Tagamet does not have the manufacturing complexity, interchangeability questions, or biologic patent thicket associated with monoclonal antibodies, insulin products, or other biologics.
What licensing deals and settlements affect Tagamet?
The important commercial transaction is the transfer of the Tagamet consumer-health brand from GSK to Prestige Brands as part of GSK’s divestiture of selected consumer products.[6] No major current patent settlement is central to Tagamet’s market position.
The absence of a meaningful settlement landscape is consistent with the product’s age. The market is driven by brand ownership, retail execution, generic pricing, and category demand rather than by active patent litigation.
How strong is the Tagamet patent estate?
The patent estate is weak as a current market-protection tool but strong as a historical case study in pharmaceutical commercialization.
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Formulation protection |
Expired or low commercial relevance |
| Method-of-use protection |
Expired |
| Orange Book exclusivity |
No meaningful current barrier |
| Trademark strength |
Potentially valuable |
| Generic vulnerability |
High |
| Manufacturing complexity |
Low to moderate |
| Biosimilar exposure |
Not applicable |
| Litigation leverage |
Limited on patents; greater on trademarks and branding |
The brand can remain commercially viable without a live patent estate because consumers may pay for recognition, availability, and perceived reliability. That support is weaker where a close branded substitute, Pepcid, occupies the same therapeutic category.
What are the likely generic and commercial launch scenarios?
A new generic launch would not materially disrupt the market because generic cimetidine already exists. The more relevant scenarios concern branded competition and retail positioning.
Base case
Tagamet remains a mature OTC brand with stable distribution and gradual volume pressure. Pricing remains constrained by generic and branded alternatives.
Competitive downside
Pepcid and proton-pump inhibitor brands capture more H2 and heartburn demand. Retailers reduce Tagamet shelf space, and private-label products increase their share.
Product-line upside
A differentiated combination, improved packaging, or targeted OTC positioning could support incremental sales. The opportunity would depend on FDA compliance, consumer demand, and evidence that the product solves a distinct use case.
Geographic coverage
Cimetidine remains available in multiple markets through generic manufacturers, but brand strength varies by country. In the United States, the brand is mainly an OTC consumer-health proposition. In other jurisdictions, local generic substitution, prescription regulation, and brand ownership may produce different commercial outcomes.
Key Takeaways
- Tagamet is the original cimetidine brand and was a landmark prescription H2 blocker.
- Its historical blockbuster revenue came from strong clinical demand and long-lived prescription exclusivity.
- Core cimetidine patents and method-of-use rights expired decades ago.
- Generic cimetidine has eliminated meaningful prescription pricing power.
- Current value is concentrated in Tagamet HB, trademark recognition, and retail distribution.
- Pepcid is the closest branded competitor; proton-pump inhibitors compete for stronger acid suppression.
- Tagamet is not a biologic and has no biosimilar exposure.
- Current public disclosures do not provide a reliable standalone Tagamet revenue series.
- The financial outlook is mature, low-growth, and vulnerable to OTC substitution.
- The principal remaining risks involve brand erosion, retail execution, supply, labeling, and consumer preference rather than patent expiry.
FAQs
Is Tagamet still sold in the United States?
Tagamet HB has historically been sold as an OTC cimetidine product in the United States, while prescription cimetidine is available primarily through generic manufacturers.
Is cimetidine more effective than famotidine?
Both are H2-receptor antagonists, but cimetidine has a broader drug-interaction profile. Famotidine is often preferred when clinicians want to reduce interaction concerns.
Does Tagamet have an active composition patent?
No. The original composition-of-matter protection for cimetidine expired long ago, allowing generic competition.
Can a company launch a generic Tagamet product without a license from the brand owner?
A company generally does not need a brand-owner license to market an approved generic cimetidine product after relevant patent and regulatory barriers have expired. It must obtain FDA approval and avoid unauthorized use of the Tagamet trademark and trade dress.
Is Tagamet a potential target for pharmaceutical licensing?
Tagamet is more likely to interest a consumer-health company seeking a recognized OTC acid-control brand than an innovative pharmaceutical company seeking patent-protected technology. Licensing value would depend on geographic rights, brand positioning, distribution, and formulation opportunities.
References
-
U.S. Food and Drug Administration. (n.d.). Cimetidine prescribing information and drug database records. FDA.
-
Sneader, W. (2005). Drug discovery: A history. John Wiley & Sons.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. National Library of Medicine. (n.d.). Cimetidine: Drug information. MedlinePlus.
-
U.S. Food and Drug Administration. (2020). FDA requests removal of all ranitidine products from the market. FDA.
-
GSK. (2011). GSK announces agreement to divest selected consumer healthcare brands to Prestige Brands. GlaxoSmithKline.
-
Prestige Consumer Healthcare Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
